{
    "2020-04-10": [
        [
            {
                "time": "2019-年报发布日",
                "original_text": "凯莱英（002821）：经营业绩稳健增长，临床阶段业务表现亮眼【2019年年报点评|西南医药朱国广/杜向阳团队】",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "经营业绩",
                        "稳健增长",
                        "临床阶段业务",
                        "亮点"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-10",
                "original_text": "大幅上调目标价策略（4月10日）",
                "features": {
                    "keywords": [
                        "目标价",
                        "上调",
                        "策略"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-年报发布日",
                "original_text": "【民生医药|年报点评】凯莱英：跨过规模化量产期，ROE有望持续提高",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "规模化量产",
                        "ROE",
                        "持续提高"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-年报发布日",
                "original_text": "凯莱英（002821）2019年年报点评：业绩持续高增长，漏斗效应显成效",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "业绩",
                        "高增长",
                        "漏斗效应",
                        "成效"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}